Bristol-Myers Squibb Company (BMY)

68.15
-0.58(-0.84%)
After Hours
68.17
+0.02(+0.03%)
- Real-time Data
  • Volume:
    8,963,714
  • Bid/Ask:
    68.09/68.14
  • Day's Range:
    68.05 - 69.27

BMY Overview

Prev. Close
68.73
Day's Range
68.05-69.27
Revenue
44.38B
Open
69
52 wk Range
56.75-69.26
EPS
-2.27
Volume
8,963,714
Market Cap
151.43B
Dividend (Yield)
1.96
(2.85%)
Average Volume (3m)
9,482,495
P/E Ratio
-
Beta
0.62
1-Year Change
15.22%
Shares Outstanding
2,222,000,000
Next Earnings Date
27 Oct 2021
What is your sentiment on Bristol-Myers Squibb Company?
or
Market is currently closed. Voting is open during market hours.

Bristol-Myers Squibb Company News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellNeutralStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyStrong Buy
SummaryStrong SellStrong SellSellStrong BuyStrong Buy

Bristol-Myers Squibb Company Company Profile

Bristol-Myers Squibb Company Company Profile

Employees
30250

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; and DarwinHealth, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.